2017年乳腺癌新辅助治疗进展

doi:10.6040/j.issn.1671-7554.0.2017.896

摘要/Abstract

摘要： 乳腺癌的新辅助治疗包括在手术之前进行的化疗、内分泌治疗、靶向治疗等。肿瘤组织对于新辅助治疗的反应与疗效密切相关,甚至可能关系到患者治疗后的生存,特别是病理完全缓解(pCR)已经被提出作为临床效益预测的替代终点,新辅助治疗提供的这些信息为下一步治疗方案的制定指明了方向。近年来,对于新辅助治疗的研究不断深入,一些重要临床研究的结果也在不断更新并被重新解读,使我们的理念也在随之改变。在本文中我们简述了2017年有关新辅助治疗方面的新进展。

关键词: 乳腺癌, 新辅助治疗, 进展, 化疗, 内分泌治疗, 靶向治疗

Abstract: Neoadjuvant therapy is critical for treatment in patients with breast cancer, including chemotherapy, endocrine therapy, targeted therapy and so on. The response of tumor tissue, especially pathological complete response(PCR)has been proposed as a surrogate endpoint for prediction of long-term clinical benefit.The neoadjuvant therapy also provides information of tumor response and improves further therapeutic strategies. Recently, substantial developments have been made in neoadjuvant therapy with important clinical trials, and our concept of neoadjuvant therapy is also changing. This review showed the current perspectives in neoadjuvant therapy in 2017.

Key words: Breast cancer, Neoadjuvant therapy, Advance, Chemotherapy, Endocrine therapy, Targeted therapy

中图分类号:

R737.9

陈波,张磊. 2017年乳腺癌新辅助治疗进展[J]. 山东大学学报 (医学版), 2018, 56(1): 12-16.

CHEN Bo, ZHANG Lei. Current perspectives of neoadjuvant therapy for breast cancer in 2017[J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 12-16.

参考文献

[1] Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database[J]. J Am Coil Surg, 2015, 220(6): 1063-1069.
[2] King TA, Mowow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy[J]. Nat Rev Clin Oncol, 2015, 12(6): 335-343.
[3] Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer[J]. N Engl J Med, 2012, 366(26): 2438-2441.
[4] von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J]. J Clin Oncol, 2012, 30(15): 1796-1804.
[5] Cortazar P, Zhang L, Untch M, et a1. Pathological complete response and long-term clinical benefit in breast cancer: the CT-NeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
[6] Untch M, Konecny GE, Paepke S, et al. Current and future role of neoadjuvant therapy for breast cancer[J]. Breast, 2014, 23(5): 526-537.
[7] Amiri-Kordestani L, Beaver JA, Cortazar P. Neoadjuvant therapy as a platform for drug development: current controversies and regulatory respectives[J]. Oncology(Williston Park), 2015, 29(11): 843-844.
[8] DeMichele A, Yee D, Berry DA, et al. The neoadjuvant model is still the future for drug development in breast cancer[J]. Clin Cancer Res, 2015, 21(13): 2911-2915.
[9] Sibylle L, Guatavo W, Valentina N, et al. Impact in delay of start of chemotherapy and surgery on PCR and survival in Breast cancer-a pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials[C]. 2017 ASCO,Abstract 571. https://www.asco.org/
[10] Anna W, Sami B, Kenneth H, et al. Effect of neoadjuvant chemotherapy regimen choice in breast cancer patients with pathologic complete response[C]. 2017 ASCO, Abstract 570. https://www.asco.org/
[11] Silverd P, Richardsona L, Eklunda C, et al. Efficacy of neoadjuvant eisplatin in triple-negative breast cancer[J]. J Clin Oncol, 2010, 28(7): 1145-1153.
[12] Oakman C, Viale G, DiLeo A. Management of triple negative breast cancer[J]. Breast, 2010, 19(5): 312-321.
[13] Dent R, Trudeau M, Pritehard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15Pt1): 4429-4434.
[14] Von MG, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatinin patients with triple-negative and Her-2-positive early breast cancer(GeparSixto; GBG 66): a randomised phase 2 trial[2]. Lancet Oncol, 2014, 15(7): 747-756.
[15] Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and /or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603(Alliance)[J]. J Clin Oncol, 2015, 33(1): 13-21.
[16] Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer[J]. N Engl J Med, 2016, 375(1): 23-34.
[17] Daniel E, Nathaly PN, Hugo AF, et al. Improving pathological responses in locally advanced triple negative breast cancer comparison between CbD and AT-T regimens[C]. 2017 ASCO,Abstract 585. https://www.asco.org/
[18] Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 76(22): 2147-2159. doi: 10.1056/NEJMoa1612645.
[19] von Minckwitz G, Blohmer JU, Costa SD, et al. Response-guided neoadjuvant chemotherapy for breast cancer[J]. J Clin Oncol, 2013, 31(29): 3623-3630. doi: 10.1200/JCO.2012.45.0940.
[20] Hee JK, Woo CN, Eun Sook L, et al. A phase III, open label, prospective, randomized, multicenter, neoadjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, breast cancer(KBCSG 012)[C]. 2017 ASCO, NEST Trial. https://www.asco.org/
[21] Gianni L, Pienkowski T, Im YH, et al. 5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-pOSitive breast cancer(Neosphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800.
[22] Jens H, Eileen H, JOSe B, et al. Survival outcomes of the neoaltto study: updated results of a randomized multicenter phase 3 neoadjuvant trial[C]. 2017 ASCO,Abstract 512. https://www.asco.org/
[23] van Ramshorst MS, van Werkhoven E, Mandjes IA, et al. A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-pOSitive breast cancer: the TRAIN-2 study(BOOG 2012-03)[C]. 2017 ASCO,Abstract 507. https://www.asco.org/
[24] Justin S, Yauheni VB, Valery B, et al. Double-blind, randomized phase 3 study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate, versus reference trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer[C]. 2017 ASCO,Abstract 510. https://www.asco.org/
[25] Rita N, Minetta C, Liu, et al. Pembrolizum ab plus standard neoadjuvant therapy for high-risk breast cancer: Result from the I-SPY 2 Trial[C]. 2017 ASCO,I-SPY 2 Trial. https://www.asco.org/

相关文章 15

[1]	古春青,郭睿思,周勤勤,刘恒辉,巴婉玉,孙士玲,王冰,郑玉玲,吴宿慧. 基于网络药理学和动物实验探讨酸枣仁-远志药对治疗乳腺癌相关性失眠的作用机制[J]. 山东大学学报 (医学版), 2026, 64(1): 99-108.
[2]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[3]	王雪梅,杨豪,宋洋,程世超,张婷婷,王艳春. 抗糖尿病药物与女性恶性肿瘤的因果关联:一项两样本孟德尔随机化分析[J]. 山东大学学报 (医学版), 2025, 63(6): 67-77.
[4]	崔倩倩,李金鹏,吴豫丹,侯志平,孙玮螺,崔盼盼,何培元. 粪便miRNA对结直肠进展期腺瘤无创筛查的临床价值[J]. 山东大学学报 (医学版), 2025, 63(2): 43-50.
[5]	余之刚,郑超. 乳腺癌多学科诊疗的现状、挑战与创新模式[J]. 山东大学学报 (医学版), 2025, 63(1): 1-9.
[6]	山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16.
[7]	程跃启,王斐,于理想,郑超,余之刚. 曲妥珠单抗致HER2阳性乳腺癌患者心脏毒性的研究进展[J]. 山东大学学报 (医学版), 2025, 63(1): 17-24.
[8]	王敏, 李习平, 檀军, 邱梅, 侯泽宇, 田莹, 罗鸿莹, 范超文, 齐玲, 俞琦, 谢薇. 慢病毒载体介导Gag-Caspase-8诱导三阴性乳腺癌原代细胞凋亡及S期阻滞[J]. 山东大学学报 (医学版), 2025, 63(1): 25-34.
[9]	张洁,张芳芳,王靖楠,李泽宇,宋颖,李娜. circ_0000144在乳腺癌中的表达及其对乳腺癌细胞增殖、迁移和侵袭能力的影响[J]. 山东大学学报 (医学版), 2025, 63(1): 35-42.
[10]	宋雅雯,郭联涛,孔德光,孙圣荣. VTCN1导致HR+乳腺癌预后不良及内分泌治疗耐药[J]. 山东大学学报 (医学版), 2025, 63(1): 43-59.
[11]	刘晶晶,庞婧,赵晓丹,林昕,付敏,陈静静. 基于乳腺X线摄影及DCE-MRI机器学习模型预测乳腺癌新辅助治疗后病理完全缓解:双中心研究[J]. 山东大学学报 (医学版), 2025, 63(1): 60-72.
[12]	孙婧,杨瑞敏,王聪,张月,罗兵. 基于术前超声、炎症指标及超声影像组学联合模型预测乳腺癌腋窝淋巴结转移[J]. 山东大学学报 (医学版), 2025, 63(1): 73-80.
[13]	李永,崔书君,杨飞,张凡,殷晓霞. 基于增强MRI的亚区域影像组学模型可预测乳腺癌患者新辅助化疗后的病理完全反应[J]. 山东大学学报 (医学版), 2025, 63(1): 81-89.
[14]	袁宗怀,潘广晔,迟曰梅,安传国,张永刚. 孟德尔随机化分析低级别浆液性卵巢癌与乳腺癌的因果关系[J]. 山东大学学报 (医学版), 2025, 63(1): 99-107.
[15]	艾宪程,王斐,周文重,于理想,周飞,相玉娟,李亮,余之刚. 山东省38所三甲医院乳腺多学科诊疗现状[J]. 山东大学学报 (医学版), 2025, 63(1): 108-114.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed